"En lo que se refiere al tratamiento, además de las técnicas más avanzadas de radiología, HM CIOCC cuenta con la unidad de investigación traslacional, que posibilita un abordaje personalizado de cada tipo de tumor. Ejemplos de servicios de máximo nivel en este sentido son la Unidad de Radiología de la Mujer o el Servicio de Oncología Radioterápica, con tres aceleradores lineales -uno de ellos casi único en España, que permite hacer cirugía intra y extracraneal-, un quirófano inteligente y braquiterapia. HM CIOCC también cuenta con un área dedicada a investigación, tanto el Laboratorio de Dianas Terapéuticas como en el Servicio de Oncología Radioterápica."

During the past decade, Start Madrid - Ciocc conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 2 clinical trials were completed, i.e. on average, 13.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Start Madrid - Ciocc" #1 sponsor was "Genmab" with 3 trials, followed by "OncoMed Pharmaceuticals, Inc." with 2 trials sponsored, "ACEA Therapeutics, Inc." with 1 trials sponsored, "BeiGene" with 1 trials sponsored and "Boston Pharmaceuticals" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Start Madrid - Ciocc" #1 collaborator was "Novotech (Australia) Pty Limited" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "BioNTech SE" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "H3 Biomedicine Inc." with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Start Madrid - Ciocc" are "Triple Negative Breast Cancer" (3 trials), "Advanced Solid Tumors" (2 trials), "Non Small Cell Lung Cancer" (2 trials), "Non-small Cell Lung Cancer" (2 trials) and "Pancreatic Cancer" (2 trials). Many other conditions were trialed in "Start Madrid - Ciocc" in a lesser frequency.

Most popular intervention types in "Start Madrid - Ciocc" are "Drug" (14 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Demcizumab" (2 trials), "AC0010MA" (1 trials), "Abraxane®" (1 trials), "BOS172738" (1 trials) and "CX-072" (1 trials). Other intervention names were less common.

The vast majority of trials in "Start Madrid - Ciocc" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Start Madrid - Ciocc". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Start Madrid - Ciocc, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Start Madrid - Ciocc, 14 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".